ILK and breast carcinoma: In this study, we used small-molecule inhibitors and genetic knockdown to examine the role of mTORC2 versus ILK as the PDK2 in PTEN-negative LNCaP and PC-3 prostate and MDA-MB-468 breast cancer cell lines.